Diabetes drug semaglutide may lower dementia risk, huge study suggests

NCT ID NCT05768945

Completed Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at medical records from over 740,000 older adults with diabetes to see if those taking semaglutide had a lower risk of developing dementia compared to those on other diabetes drugs (DPP4 inhibitors). The goal was to find out if semaglutide might help protect the brain. Because this is an analysis of existing data, it can suggest a link but cannot prove that semaglutide directly prevents dementia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If semaglutide is linked to lower dementia risk, this could point toward repurposing it to prevent Alzheimer's in people with diabetes.
What could go wrong: This is an observational analysis, not a controlled trial. It can show links but not prove cause and effect. Results may not apply to people without diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.